TIMP1 and glioblastoma: The present study suggests that scoring of TIMP-1 immunoreactivity is a better choice than measuring of TIMP-1 plasma levels or using TIMP-1/CEN-X ratios, in future studies evaluating TIMP-1 as a biomarker in glioblastomas.